

Figure S1. Transfection efficiency of pcDNA3.1-GRINAp plasmid in LoVo cells. GRIN A (A) mRNA and (B) protein expression levels were determined by reverse transcription-quantitative PCR and western blotting. $^{**}P<0.01$ vs. NC plasmid. GRIN A, glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1; NC, negative control; OE, overexpression.




Table SI. Clinical characteristics of patients with colorectal cancer.

Clinical characteristic	Case, n (%)
Age, years	
<60	52 (32.3)
≥60	109 (67.7)
Sex	
Male	80 (49.7)
Female	81 (50.3)
T stage	
T1 and T2	52 (32.2)
T3 and T4	109 (67.7)
Lymphatic invasion	
Absent	77 (47.8)
Present	84 (52.2)
Differentiation	
Well	35 (21.7)
Moderate	70 (43.5)
Poor	56 (34.8)
TNM stage	
I	20 (12.4)
II	57 (35.4)
III	84 (52.2)
Tumor location	
Colon	73 (45.3)
Rectum	88 (54.7)

Table SII. Sequences of shRNAs used in the present study.

shRNA	Sequence (5'→3')
shGRINA	F: GGUUGUGCGUACAAAGCACTT R: GUGCUUUGUACGCACAACCTT
shNC	F: UUCUCCGAACGUGUCACGUTT R: ACGUGACACGUUCGGAGAATT
shRNA, short hairpin RNA; F, forward; R, reverse; NC, negative control; GRINA, glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1.	